The submission was based on positive results from a multi-stage clinical trial program which included more than 250 children and adults with hemophilia A worldwide
The medication is indicated for on-demand treatment and control of bleeding episodes.
Update: Shire has issued a new statement regarding the injunction.
In the past few weeks, we have received many inquiries regarding the scope of the injunction Shire is seeking in its lawsuit against Genentech/Roche.
Medscape recently launched a new education opportunity for healthcare providers.
BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.
The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.
This agreement allows Shire to conduct research on the use of Rani Pill™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A.
Spark provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, SPK-8011 and SPK-9001.
Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with h
Alnylam is developing the therapy to treat patients with hemophilia A and B, both with and without inhibitors.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car